GlassScriptPhysician profile
Jon-Paul Harmer
NPI 1568422269
$4,458.03
in general payments reported to CMS, 2019-2025
34 companies · $524 in 2025
The $524 reported for 2025 was more than what 91% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $178 · 2021: $422 · 2022: $531 · 2023: $323 · 2024: $1,887 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792 · Travel and Lodging: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.48 |
| Travel and Lodging | $941.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,976.65 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16, General - Pain Management |
| Nevro Corp. | $291.30 | 2019-2020 | |
| Abbvie INC. | $291.10 | 2021-2025 | |
| Abbott Laboratories | $244.65 | 2019-2024 | Proclaim |
| Collegium Pharmaceutical, INC. | $228.13 | 2019-2025 | Belbuca, Xtampza |
| Biotronik Nro, INC. | $121.55 | 2025 | Prospera |
| Vertex Pharmaceuticals Incorporated | $120.37 | 2024-2025 | |
| Medtronic, INC. | $113.31 | 2021-2023 | Intellis Adaptivestim |
| Zimvie INC. | $99.21 | 2023 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spinal Simplicity, LLC | $89.83 | 2023-2025 | Ha Minuteman G3-R |
| Painteq LLC | $87.28 | 2021-2022 | |
| Horizon Therapeutics Plc | $86.27 | 2019-2022 | |
| Biogen, INC. | $74.84 | 2019-2023 | Spinraza |
| Foundation Fusion Solutions, LLC | $64.75 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $54.87 | 2019-2020 | |
| Nalu Medical, INC. | $46.66 | 2025 | Nalu Neurostimulation System |
| Grt US Holding, INC. | $43.77 | 2021-2022 | |
| Pfizer INC. | $42.21 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $33.65 | 2019-2020 | |
| Valinor Pharma, LLC | $31.63 | 2025 | Movantik |
| Arbor Pharmaceuticals, INC. | $30.09 | 2021 | |
| Scilex Pharmaceuticals INC. | $20.44 | 2022 | |
| Forte Bio-Pharma LLC | $19.06 | 2022 | |
| Lilly USA, LLC | $17.25 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.17 | 2019 | |
| Ibsa Pharma INC. | $16.02 | 2024 | Tirosint, Licart |
| Si-Bone, INC. | $15.84 | 2020 | |
| Redhill Biopharma INC. | $15.30 | 2021 | |
| Spr Therapeutics, INC | $14.90 | 2023 | Sprint Pns System |
| Ultragenyx Pharmaceutical INC. | $14.10 | 2020 | |
| Avanos Medical | $13.94 | 2024 | Coolief* Cooled Radiofrequency |
| Vertiflex, INC. | $13.62 | 2019 | |
| Biodelivery Sciences International, INC. | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon-Paul Harmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.